Found 5 matching trials
A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007) PHASE2 This is a two-part (Phase 2/Phase 3) study of frespaciguat, an inhaled solu...
Show More Location
University of California San Diego Health-Pulmonary Critical Care ( Site 0061)
Learn More & Join Trial
A Study of Single Doses of Frespaciguat (MK-5475) on Pulmonary Vascular Resistance (MK-5475-002) PHASE1 This study of frespaciguat in participants with Group 1 pulmonary arterial ...
Show More Location
Republican Clinical Hospital of Moldova ( Site 0001)
Learn More & Join Trial
Frespaciguat (MK-5475) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006) PHASE1 The primary objectives of this study are to assess the safety/tolerability ...
Show More Location
Lexington VA- Health Care System ( Site 0034)
Learn More & Join Trial
Frespaciguat (MK-5475) in Participants With Hypoxemia Due to COVID-19 Pneumonia (MK-5475-009) PHASE1 The purpose of this study is to evaluate safety, tolerability, and pharmaco...
Show More Location
Multiple Locations
Learn More & Join Trial
Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD PHASE2 Researchers are looking for ways to treat pulmonary hypertension (PH) cause...
Show More Status
Active Not Recruiting
Location
UCSF Helen Diller Medical Center at Parnassus Heights ( Site 0110)
Learn More & Join Trial